TrialBlood cancer journal2021

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.

Franck Morschhauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.